Shares of Seres Therapeutics are up 16c, or 18% to $1.06 in early trading, which traders attribute to an M&A rumor being highlighted in the Betaville blog, contacts tell The Fly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics Releases Financial Statements Ahead of Asset Sale
- Seres Therapeutics Unveils Updated Corporate Presentation
- Seres Therapeutics sees cash runway into 4Q25 upon VOWST sale close
- Seres Therapeutics reports Q2 EPS (22c), consensus (27c)
- Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates